✦ LIBER ✦

0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer

✍ Scribed by A. Schneeweiss; A. Ruiz; P. Rovira; A. Bottini; A. Manikhas; J. Wacker; T. Schumacher; M. Wolf; M. Segui; P. Sinn; L. Kennedy; K. Mansouri; T. Bauknecht

Book ID: 114316307
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 54 KB
Volume: 18
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(09)70201-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxorubicin/Pemetrexed Followed by Docet

Doxorubicin/Pemetrexed Followed by Docetaxel Versus Doxorubicin/Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early-Stage Breast Cancer: A Randomized Phase II Trial

✍ Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez- 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 88 KB

Toxicity of Dose-Dense Docetaxel Followe

Toxicity of Dose-Dense Docetaxel Followed by Doxorubicin with Cyclophosphamide as Adjuvant Therapy for Breast Cancer in a Phase II Study

✍ Rosemary Lambert-Falls; Susan Modugno 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB

A Phase II Study of Sequential Docetaxel

A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer

✍ Antonio Antón; Javier Hornedo; Ana Lluch; Bartomeu Massuti; Mónica Corral; Ramon 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB

A randomized phase-III trial of docetaxe

A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer

✍ Keun Seok Lee; Jungsil Ro; Byung-Ho Nam; Eun Sook Lee; Youngmee Kwon; Hye Soo Kw 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 285 KB

A dose-dense schedule of docetaxel follo

A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study

✍ Silvia Antolín; Ramón Mel; Manuel Ramos; Andrés García-Palomo; Concepción Almanz 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 118 KB

Phase II study of liposome-encapsulated

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

✍ Saracchini, S.; Foltran, L.; Tuccia, F.; Bassini, A.; Sulfaro, S.; Micheli, E.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 548 KB